Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New gel injections aim to smooth cheek wrinkles

NCT ID NCT07344584

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This pilot study will test the safety and effectiveness of two injectable gels, GP0122 and GP0124, for reducing lines and wrinkles in the cheek area. About 60 adults with moderate to severe cheek wrinkles will receive the treatment and be followed for 12 months. The main goal is to check for side effects and pain, with secondary goals looking at wrinkle improvement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Injectable gel (GP0122 and GP0124)
What this could lead to
If successful, this could lead to a new, safe option for reducing cheek wrinkles.
What could go wrong
This is a small, early pilot study with only 60 participants. It focuses on safety first, so effectiveness is not yet proven. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adult males or non-pregnant, non-breastfeeding adult females. 1. Participants with a GCWS At Rest score of Moderate or Severe on EACH side of the face, or Participants with a CSQS-CL score of Moderate, Severe, or Very severe on EACH side of the face. 2. Intent to undergo treatment for correction of lines and wrinkles in the cheek region. 3. Willing to abstain from any other facial plastic, surgical or cosmetic procedures in the cheek area for the duration of the study (e.g., laser or chemical resurfacing, needling, facelift, lifting threads, radiofrequency etc.). Inclusion criteria 4-5 apply only to female participants of childbearing potential: 4. Agrees to use an acceptable form of effective birth control for the duration of the study and is willing to take a urine pregnancy test (UPT) at screening, baseline and prior to receiving any study treatment. 5. Negative UPT at the screening and baseline visits. Exclusion Criteria: 1. Known/previous allergy or hypersensitivity. 2. Known/previous allergy or hypersensitivity to local anesthetics. 3. Previous facial surgery (e.g., facelift) in the treatment area that in the Treating Investigator´s opinion. 4. Any previous aesthetic procedures or implants in the treatment area. 5. Presence of any disease or lesions in the treatment area. 6. An underlying known disease, a surgical or medical condition that would expose the participant to undue risk. 7. Use of concomitant medication that have the potential to prolong bleeding times. 8. Presence of any condition or situation, which in the opinion of the Treating Investigator makes the subject unable to complete the study per protocol. 9. Women who are pregnant or breast feeding, or women of childbearing potential who are not practicing adequate contraception or planning to become pregnant during the study period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Wrinkle reduction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Galderma Investigational Site #7049

    Vancouver, V6H4E1, Canada

  • Galderma Investigational Site #8162

    Woodbridge, L4L 8E2, Canada

  • Galderma Investigational Site #8379

    Burlington, L7N3N2, Canada

  • Galderma Investigational Site #8688

    Vancouver, V5ZRE1, Canada

  • Galderma Investigational Site #8689

    Toronto, M543N8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.